Overall, our study indicates that CKB downregulation is associated with poor prognosis in prostate cancer, and CKB downregulation functionally promotes prostate cancer progression, at least in part by promoting AKT activation and EMT. This evidence concerns the gene AKT1 and prostate cancer.